Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Pharming Group N.V (PHAR) Assets Average: 2021-2025

Historic Assets Average for Pharming Group N.V (PHAR) over the last 5 years, with Sep 2025 value amounting to $460.0 million.

  • Pharming Group N.V's Assets Average rose 9.34% to $460.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $460.0 million, marking a year-over-year increase of 9.34%. This contributed to the annual value of $431.4 million for FY2024, which is 2.90% down from last year.
  • Per Pharming Group N.V's latest filing, its Assets Average stood at $460.0 million for Q3 2025, which was up 8.31% from $424.7 million recorded in Q2 2025.
  • Pharming Group N.V's Assets Average's 5-year high stood at $460.0 million during Q3 2025, with a 5-year trough of $419,425 in Q1 2021.
  • In the last 3 years, Pharming Group N.V's Assets Average had a median value of $426.4 million in 2023 and averaged $430.4 million.
  • The largest annual percentage gain for Pharming Group N.V's Assets Average in the last 5 years was 94,090.11% (2022), contrasted with its biggest fall of 51.49% (2022).
  • Over the past 5 years, Pharming Group N.V's Assets Average (Quarterly) stood at $399.1 million in 2021, then crashed by 46.61% to $213.1 million in 2022, then spiked by 111.02% to $449.7 million in 2023, then declined by 8.21% to $412.7 million in 2024, then increased by 9.34% to $460.0 million in 2025.
  • Its last three reported values are $460.0 million in Q3 2025, $424.7 million for Q2 2025, and $401.6 million during Q1 2025.